CyDex, Inc. Licenses Captisol(R) to Sunesis Pharmaceuticals, Inc. (SNSS) for Oncology Drug Candidate  
5/3/2007 12:20:17 PM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced an agreement licensing its Captisol® enabling technology to Sunesis Pharmaceuticals, Inc. for formulation of a selective Aurora kinase inhibitor with potent anti-tumor activity across a number of nonclinical human cancer models.